ITRM20030355A1 - Composti ad attivita' citotossica derivati della combretastatina. - Google Patents

Composti ad attivita' citotossica derivati della combretastatina.

Info

Publication number
ITRM20030355A1
ITRM20030355A1 IT000355A ITRM20030355A ITRM20030355A1 IT RM20030355 A1 ITRM20030355 A1 IT RM20030355A1 IT 000355 A IT000355 A IT 000355A IT RM20030355 A ITRM20030355 A IT RM20030355A IT RM20030355 A1 ITRM20030355 A1 IT RM20030355A1
Authority
IT
Italy
Prior art keywords
combretastatine
derivatives
compounds
cytotoxic activities
cytotoxic
Prior art date
Application number
IT000355A
Other languages
English (en)
Inventor
Domenico Alloatti
Giuseppe Giannini
Claudio Pisano
Romeo Romagnoli
Daniele Simoni
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT000355A priority Critical patent/ITRM20030355A1/it
Publication of ITRM20030355A0 publication Critical patent/ITRM20030355A0/it
Priority to CNA2004800207571A priority patent/CN1826330A/zh
Priority to MXPA06000625A priority patent/MXPA06000625A/es
Priority to US10/563,465 priority patent/US20060160773A1/en
Priority to JP2006520106A priority patent/JP2007530427A/ja
Priority to EP04745198A priority patent/EP1646616A2/en
Priority to CA002531389A priority patent/CA2531389A1/en
Priority to KR1020067001052A priority patent/KR20060039001A/ko
Priority to BRPI0412744-7A priority patent/BRPI0412744A/pt
Priority to AU2004257011A priority patent/AU2004257011A1/en
Priority to PCT/IT2004/000373 priority patent/WO2005007635A2/en
Priority to TW093120812A priority patent/TW200504042A/zh
Priority to ARP040102518A priority patent/AR045700A1/es
Publication of ITRM20030355A1 publication Critical patent/ITRM20030355A1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/70—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/70—Nitro radicals
    • C07D307/71—Nitro radicals attached in position 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
    • C07D333/44—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms attached in position 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT000355A 2003-07-18 2003-07-18 Composti ad attivita' citotossica derivati della combretastatina. ITRM20030355A1 (it)

Priority Applications (13)

Application Number Priority Date Filing Date Title
IT000355A ITRM20030355A1 (it) 2003-07-18 2003-07-18 Composti ad attivita' citotossica derivati della combretastatina.
PCT/IT2004/000373 WO2005007635A2 (en) 2003-07-18 2004-07-06 Combretastatin derivatives with cytotoxic action
CA002531389A CA2531389A1 (en) 2003-07-18 2004-07-06 Combretastatin derivatives with cytotoxic action
MXPA06000625A MXPA06000625A (es) 2003-07-18 2004-07-06 Derivados de combretastatina con accion citotoxica.
US10/563,465 US20060160773A1 (en) 2003-07-18 2004-07-06 Combretastatin derivatives with cytotoxic action
JP2006520106A JP2007530427A (ja) 2003-07-18 2004-07-06 細胞毒性作用を有するコンブレタスタチン誘導体
EP04745198A EP1646616A2 (en) 2003-07-18 2004-07-06 Combretastatin derivatives with cytotoxic action
CNA2004800207571A CN1826330A (zh) 2003-07-18 2004-07-06 具有细胞毒性作用的考布他汀衍生物
KR1020067001052A KR20060039001A (ko) 2003-07-18 2004-07-06 세포독성 작용을 갖는 콤브레타스타틴 유도체
BRPI0412744-7A BRPI0412744A (pt) 2003-07-18 2004-07-06 derivados de combretastatina com ação citotóxica
AU2004257011A AU2004257011A1 (en) 2003-07-18 2004-07-06 Combretastatin derivatives with cytotoxic action
TW093120812A TW200504042A (en) 2003-07-18 2004-07-12 Combretastatin derivatives with cytotoxic action
ARP040102518A AR045700A1 (es) 2003-07-18 2004-07-16 Derivados de combretastatina que presentan actividad citotoxica

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000355A ITRM20030355A1 (it) 2003-07-18 2003-07-18 Composti ad attivita' citotossica derivati della combretastatina.

Publications (2)

Publication Number Publication Date
ITRM20030355A0 ITRM20030355A0 (it) 2003-07-18
ITRM20030355A1 true ITRM20030355A1 (it) 2005-01-19

Family

ID=29765925

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000355A ITRM20030355A1 (it) 2003-07-18 2003-07-18 Composti ad attivita' citotossica derivati della combretastatina.

Country Status (13)

Country Link
US (1) US20060160773A1 (it)
EP (1) EP1646616A2 (it)
JP (1) JP2007530427A (it)
KR (1) KR20060039001A (it)
CN (1) CN1826330A (it)
AR (1) AR045700A1 (it)
AU (1) AU2004257011A1 (it)
BR (1) BRPI0412744A (it)
CA (1) CA2531389A1 (it)
IT (1) ITRM20030355A1 (it)
MX (1) MXPA06000625A (it)
TW (1) TW200504042A (it)
WO (1) WO2005007635A2 (it)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ560712A (en) 2005-02-17 2010-12-24 Synta Pharmaceuticals Corp (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders
JP5149177B2 (ja) * 2005-07-25 2013-02-20 シンタ ファーマシューティカルズ コーポレーション 増殖性疾患の治療のための、チューブリンポリマー化の１，２，３−トリアゾール系抑制剤
US7781580B2 (en) * 2007-04-23 2010-08-24 Virginia Commonwealth University Stilbene derivatives as new cancer therapeutic agents
JP5302328B2 (ja) 2007-11-21 2013-10-02 オキシジーン， インコーポレイテッド 造血性新生物を治療するための方法
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
CN102249987B (zh) * 2011-05-06 2013-07-24 兰州大学 一种考布他汀类化合物及其制备方法和用途
CN102863388B (zh) * 2011-07-05 2015-04-29 南京圣和药业股份有限公司 肿瘤靶向药物Combretastatin A4衍生物
WO2013047813A1 (ja) 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
PL220039B1 (pl) * 2012-03-29 2015-08-31 Univ Medyczny Im Karola Marcinkowskiego W Poznaniu Nowe pochodne (Z)-1,2-difenyloetenu
CN102993115B (zh) * 2012-12-08 2015-09-30 南京师范大学 一种3,5–二取代异噁唑啉衍生物及其合成方法和应用
JP2018523712A (ja) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
US11434190B2 (en) * 2016-12-23 2022-09-06 The University Of Queensland Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases
JP2021500392A (ja) * 2017-10-25 2021-01-07 バイエル・ファルマ・アクティエンゲゼルシャフト ベンゾチオフェン−２−イルボロネートを調製するためのプロセス

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH540247A (de) * 1967-04-21 1973-09-28 Ciba Geigy Ag Verfahren zur Herstellung von heterocyclischen, Asthylendoppelbindungen enthaltenden Verbindungen
FR2558158B1 (fr) * 1984-01-13 1986-05-16 Roussel Uclaf Derives de l'indole ethenyl phenol, leurs sels, procede de preparation, application a titre de medicaments, compositions les renfermant et intermediaires
AU8641991A (en) * 1990-09-10 1992-03-30 Rhone-Poulenc Rorer International (Holdings) Inc. Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
GB9408577D0 (en) * 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2003087072A1 (en) * 2002-03-29 2003-10-23 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for endothelial disorder

Also Published As

Publication number Publication date
WO2005007635A2 (en) 2005-01-27
CN1826330A (zh) 2006-08-30
WO2005007635A8 (en) 2005-05-12
BRPI0412744A (pt) 2006-09-26
JP2007530427A (ja) 2007-11-01
ITRM20030355A0 (it) 2003-07-18
AU2004257011A1 (en) 2005-01-27
EP1646616A2 (en) 2006-04-19
WO2005007635A3 (en) 2005-08-11
MXPA06000625A (es) 2006-04-19
CA2531389A1 (en) 2005-01-27
KR20060039001A (ko) 2006-05-04
AR045700A1 (es) 2005-11-09
US20060160773A1 (en) 2006-07-20
TW200504042A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
SI1398328T1 (sl) Hidroksialkilni derivati ĺ kroba
ITUD20030092A1 (it) Protesi per l'articolazione della spalla.
SI3127553T1 (sl) Konjugati nosilca derivatov kaliheamicina
DK1448198T3 (da) Nicotin- eller isonicotin-benzothiazolderivater
CY2017048I1 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
NO20034930L (no) Substituerte cykloheksan-1,4-diaminderivater
MXPA03000059A (es) Derivados de pirazol.
ATE340782T1 (de) Piperidinbenzolsulfonamidderivate
ATE352550T1 (de) Chinazolinderivate
ATE420066T1 (de) Amidoacetonitrilderivate
DE602004024770D1 (de) Substituierte 8-perfluoro-6,7,8,9-tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
ATE395345T1 (de) Imidazol-4-yl-ethynyl-pyridin-derivate
IS2656B (is) Nýjar besímídasólafleiður
DE602004021572D1 (de) SUBSTITUIERTE 8-PERFLUORO-6,7,8,9-TETRAHYDROPYRIMIDOi1,2-A PYRIMIDIN-4-ON-DERIVATE
DK1643984T3 (da) Anvendelse af parthenolidderivater som antileukæmiske og cytotoksske midler
ITRM20030355A0 (it) Composti ad attivita' citotossica derivati della combretastatina.
ATE354365T1 (de) N-thiazol-2-yl-benzamid-derivate
EP1590624A4 (en) INTERFEROMETERAUSRICHTUNG
DE602004007387D1 (de) 5-substituierte chinazolinonderivate
ATE449064T1 (de) Amidoacetonitrilderivate
FR2878850B1 (fr) Derives de l'inositol-1-phosphate
NO20063293L (no) Farmasoytiske forbindelser
ITMI20020597A1 (it) Derivati del probucolo
ITMI20001122A0 (it) Procedimento di sintesi di derivati antraciclinici